An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Pancreatic Cancer|Colorectal Cancer (CRC)|Breast Cancer|Lung Cancer
Interventions: DRUG: Ruxolitinib|DRUG: Capecitabine|DRUG: Regorafenib
Sponsor: Incyte Corporation